← boardnext 2027-11-30next 2028-02-28
CTMX
CytomX Therapeuticsdistress 4/10 · elevated risk$3.29-1%today-51% from 52w high
Oncology 1
Lead: Solid Tumor
Revenue
$10M
Liquidity
$129M
Runway
1.6 yrs
Shares 1y
+32%
Price & events
-42.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-10.4%
1W
+4.3%
1M
-26.2%
3M
-40.7%
6M
+35.2%
1Y
+128.1%
2Y
-40.8%
5Y
-51.5%
All
Overview
- Market Cap
- $715.15M
- Volume
- 139.76K
- 52 Week Range
- $1.76 – $6.75
- Total Shares
- 217.70M
- Float Shares
- 186.26M
- Short %
- 18.54%
- % Held by Insiders
- 0.53%
- % Held by Institutions
- 96.35%
- RVOL
- 0.03x
- Beta
- 2.08
Pipeline stages · 3 programs
CX-2051, Bevacizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CX-801, pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CX-904
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-11-30 Estimated 50% readout ~2027-12-30 | Phase 1 | CX-2051, Bevacizumab | Solid Tumor, Adult | — | recruiting |
| 2028-02-28 Estimated 50% readout ~2028-03-29 | Phase 1 | CX-801, pembrolizumab | Solid Tumor, Adult | — | recruiting |
| 2025-06-04 | Phase 1 | CX-904 | Solid Tumors | 83 | terminated |
Catalyst news & presentations · 5
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026trial initiationsecondaryPhase 2CX-2051 · Initiation of Phase 2 study in colorectal cancerSEC 8-K
- first quarter of 2026readoutPhase 1CX-2051 · Phase 1 data update in advanced CRC in at least 70 patientsSEC 8-K
- second half of 2025conferencedata presentationsecondaryPhase 1CX-801 · Initial Phase 1a translational and biomarker data in advanced melanomaSEC 8-K
- 2025-07-11safety signalCX-2051 · Grade 5 treatment-related acute kidney injury in a patient with solitary kidneySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-11HC Wainwright & Co.Buy
- 2026-03-23Piper SandlerOverweight
- 2026-03-19BarclaysOverweight
- 2026-03-18JefferiesBuy
- 2026-03-18GuggenheimBuy
- 2026-03-17WedbushOutperform
Competitors — Solid Tumor
- NVSEFNOVARTIS AG$292.0B · D3
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- INCYINCYTE CORP$23.1B · D0
- ERASErasca, Inc.$5.9B · D4
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
- BCYCBICYCLE THERAPEUTICS PLC$124M · D4
- XLOXilio Therapeutics, Inc.$50M · D1
- APREAprea Therapeutics, Inc.$8M · D6
Recent news
- 2026-07-21CTMX stock holds focus after CytomX strategy update - Ad-hoc-news.de
- 2026-07-16CytomX Therapeutics, Inc. - Common Stock (NQ: CTMX - FinancialContent
- 2026-07-08CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why - Yahoo Finance
- 2026-06-30CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits
- 2026-06-29CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
- 2026-06-29CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Value Benchmark - marketscreener.com
- 2026-06-29CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell Microcap Index - marketscreener.com
- 2026-06-29CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000E Growth Benchmark - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.